¿Cuáles son los nuevos medicamentos para el tratamiento de la psoriasis en placas?

The most recent drugs to treat plaque psoriasis would be the interleukin-23 antagonists, which are FDA approved according to the brands Skyrizi, Ilumya and Tremfya.

Interleukin-23 antagonists work by stopping interleukin-23 (IL-23), a pro-inflammatory cytokine thought to play a major part in persistent immune-mediated illnesses, such as plaque psoriasis.

Interleukin-23 antagonists are included in a broader selection of medications called biologics. Biologics are given via subcutaneous shot or intravenous infusion and so are set aside for modest to serious instances of psoriasis. Various other biologic medications include tumor necrosis factor-alpha (TNF-alpha) blockers, interleukin 12 and 23 (IL-12/23) antagonists, and interleukin 17 (IL-17) antagonists.

Systemic therapies, including biologic treatments, are only used for psoriasis which includes perhaps not responded with other remedies (topical treatments and phototherapy).

More resources for different psoriasis medications, including relevant treatment options, see treatments for Psoriasis

Brand-new therapy for Plaque Psoriasis – newest FDA Approvals

Drug management Drug Class Patient society organization FDA Approved for Psoriasis Psoriasis Indication Additional Indications
Skyrizi (risankizumab-rzaa) subcutaneous injection at weeks 0,  4, subsequently every 12 months interleukin-23 antagonist grownups AbbVie Inc. 23-Apr-2019
  • moderate-to-severe plaque psoriasis
  • none
Cimzia (certolizumab pegol) subcutaneous treatment every 2 weeks tumefaction necrosis factor (TNF) blocker grownups UCB, Inc. 24-May-2018
  • moderate-to-severe plaque psoriasis
  • rheumatoid arthritis
  • psoriatic arthritis
  • ankylosing spondylitis
  • Crohn’s disease
  • non-radiographic axial spondyloarthritis
Ilumya (tildrakizumab-asmn) subcutaneous shot at months 0, 4, next every 12 days interleukin-23 antagonist grownups sunlight Pharmaceutical Industries, Inc. 20-Mar-2018
  • moderate-to-severe plaque psoriasis
  • none
Tremfya (guselkumab) subcutaneous injection at days 0, 4, next every 8 weeks interleukin-23 antagonist grownups Janssen Biotech, Inc. 13-Jul-2017
  • moderate-to-severe plaque psoriasis
  • psoriatic arthritis
Siliq (brodalumab) subcutaneous treatment at months 0, 1, and 2, subsequently every two weeks interleukin-17A antagonist grownups Bausch Health agencies Inc. 15-Feb-2017
  • moderate-to-severe plaque psoriasis in customers who have neglected to react or have lost reaction to additional systemic therapies
  • none
Taltz (ixekizumab) subcutaneous shot at weeks 0, 2, 4, 6, 8, 10, and 12, then every four weeks interleukin-17A antagonist adults and kids 6 decades and more mature Eli Lilly and organization 22-Mar-2016
  • moderate-to-severe plaque psoriasis
  • psoriatic arthritis
  • ankylosing spondylitis
  • non-radiographic axial spondyloarthritis
Cosentyx (secukinumab) subcutaneous injection at months 0, 1, 2, 3, and 4, after that every 4 weeks interleukin-17A antagonist grownups Novartis Pharmaceuticals Corporation 21-Jan-2015
  • moderate-to-severe plaque psoriasis
  • psoriatic arthritis
  • ankylosing spondylitis
  • non-radiographic axial spondyloarthritis
Otezla (apremilast) oral tablets double daily phosphodiesterase 4 (PDE4) inhibitor adults Celgene Corporation 23-Sep-2014
  • moderate-to-severe plaque psoriasis
  • psoriatic arthritis
  • oral ulcers involving Behçet’s Disease
Stelara (ustekinumab) subcutaneous shot at months 0 and 4, next every
12 days
interleukin-12 and -23 antagonist grownups and children 12 many years and older Janssen Biotech, Inc. 25-Sep-2009
  • moderate-to-severe plaque psoriasis
  • psoriatic arthritis
  • Crohns disease
  • ulcerative colitis
Humira (adalimumab) subcutaneous injection at weeks 0 and 1, next every 14 days tumefaction necrosis element (TNF) blocker adults AbbVie Inc. 18-Jan-2008
  • moderate to serious persistent plaque psoriasis when different general therapies are clinically less appropriate
  • rheumatoid arthritis
  • juvenile idiopathic arthritis
  • psoriatic arthritis
  • ankylosing spondylitis
  • Crohn’s disease
  • ulcerative colitis
  • hidradenitis suppurativa
  • uveitis
Remicade (infliximab) intravenous infusion at weeks 0, 2 and 6, subsequently every 8 weeks tumefaction necrosis factor (TNF) blocker grownups Janssen Biotech, Inc. 26-Sep-2006
  • chronic serious plaque psoriasis when some other systemic therapies tend to be medically much less appropriate
  • rheumatoid arthritis
  • psoriatic arthritis
  • ankylosing spondylitis
  • Crohn’s disease
  • ulcerative colitis
Enbrel (etanercept) grownups: subcutaneous treatment twice regular for 3 months next once weekly
young ones: subcutaneous shot when weekly
cyst necrosis factor (TNF) blocker adults and children 4 decades and older Amgen Inc. 30-Apr-2004
  • chronic average to extreme plaque psoriasis
  • rheumatoid arthritis
  • juvenile idiopathic arthritis
  • psoriatic arthritis
  • ankylosing spondylitis

The biosimilars the tumefaction necrosis aspect (TNF) blockers HumiraRemicade, and Enbrel are also Food And Drug Administration accepted for the treatment of plaque psoriasis:

Humira (adalimumab) Biosimilars

Remicade (infliximab) Biosimilars

Enbrel (etanercept) Biosimilars

For considerably more details, see Psoriasis: treatments to deal with the problems & surface

like that:https://vardenafilocomprar.com